Bristol-Myers Squibb's first-quarter performance showcased a solid expansion in its growth portfolio, offsetting legacy declines and setting the stage for a critical second half of the year packed with pivotal clinical readouts.
Bristol-Myers Squibb reported a highly transitional fourth quarter, showcasing the company's aggressive pivot toward its newer therapeutic portfolio. Faced with structural generic pressure, the pharmaceutical manufacturer leaned on its recently launched oncology and immunology assets to stabilize top-line performance. While management guided for a catalyst-rich 2026, impending exclusivity losses for the Eliquis franchise continue to cast a shadow over long-term international revenue.